Cerus

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cerus excels in Q4 with record growth and strategic milestones

Cerus delivered a strong performance in Q4 2022, driven by the success of the INTERCEPT Blood System and robust product revenue growth.
While facing challenges in inventory management and international expansion, the company's focus on innovation and upcoming milestones position it for future growth.
Opportunities in regulatory submissions, market expansion, and achieving cash flow breakeven in 2023 underscore Cerus' potential for sustained success and market leadership.

Cerus reports Q1 revenue dip, eyes China growth opportunities

Cerus navigated Q1 with a focus on financial stability, product adoption, and global market expansion. Despite revenue challenges, the company's strategic initiatives and successful debt refinancing position it for future growth. Addressing inventory management, label expansion, and market-specific hurdles will be key to unlocking opportunities.

Cerus (CERS) reports robust Q2 performance amidst growth challenges

Cerus delivered a strong performance in Q2, marked by revenue growth, improved margins, and effective cost management.
While facing challenges in U.S. customer ordering patterns and market penetration, the company remains well-positioned for growth.
With a focus on operational efficiency, product development, and market expansion, Cerus is poised to capitalize on growth opportunities.
The company's financial strength, coupled with strategic initiatives, sets a positive trajectory for continued progress and success.

Cerus reports robust Q3 sales, adjusts revenue guidance for 2023

Cerus shows strong sales growth, positive market sentiment, and progress in key trials. Challenges include revenue guidance adjustment due to delayed sales agreement. Opportunities lie in expanding product demand and achieving EBITDA breakeven.

Cerus surpasses 16 million kits sold, expects double-digit growth

Cerus delivered a strong performance in Q4 2023, surpassing 16 million kits sold and achieving positive non-GAAP adjusted EBITDA for the first time.
The company's focus on the platelet franchise and IFC business yielded growth, setting the stage for continued expansion in 2024.
While facing challenges in revenue expectations and market competition, Cerus remains well-positioned to capitalize on growth opportunities.
Guidance for 2024 indicates a positive outlook with expectations of sustained growth in the INTERCEPT platelet business and IFC revenue.

Cerus reports robust Q1 earnings, eyes international growth opportunities

Cerus' Q1 2024 earnings call highlighted strong financial performance, positive trial results, and reiterated revenue guidance. The company is focused on achieving breakeven non-GAAP adjusted EBITDA for the year. Challenges include regulatory progress and working capital adjustments, while opportunities exist in international market expansion and operational optimization.

Cerus excels in Q2 2024, raises revenue guidance amid global expansion

Cerus demonstrates strong financial performance, driven by global adoption of INTERCEPT. Focus on expanding sales in key markets and addressing analyst queries to sustain growth momentum. Future growth prospects look promising with a commitment to transparency and investor engagement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Thursday, March 11, 2021 at 11:00 am PT/ 2:00 pm ET. A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for

Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit

Qutoutiao Inc - ADR

Sykes Enterprises

Growth-oriented investors may be interested in the following small-cap stocks, as they represent businesses whose trailing 12-month earnings per share improved significantly on a year-over-year basis.

3 Small Caps for the Growth-Oriented Investor

Cerus Corporation's (CERS) CEO Obi Greenman on Q4 2020 Results - Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million, respectively. Total revenue was composed of (in millions, except %): Revenue by Segment   Three Months Ended       Twelve Months Ended     December 31,       December 31,     2020   2019   Change   2020

Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. The JV, which will be named “Cerus ZBK Biomedical” (CEZB), will be headquartered in Zibo, Shandong Province in eastern China. “We are honored to join fo

Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China

On Thursday, February 25, Cerus (NASDAQ:CERS) will release its latest earnings report. Benzinga's outlook for Cerus is included in the following report.

A Preview Of Cerus's Earnings

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,

Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus' unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year. Based on its fourth quarter unaudited preliminary product revenue, the Company expects full year 2020 produc

Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue

Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021. Cerus' plans to file for FDA extension of intercept platelet label from 5 to 7-day shelf life in 2021 should accelerate US-wide adoption of Intercept platelets.

Cerus Update: Tailwinds Now Include FDA Approval Of Cryoprecipitate Product

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provides services and blood products in the state of Minas Gerais, and the Hemocentro of Belo Horizonte – the largest blood service of HemoMinas – distributes approximately 25,000 platelet doses to hospi

Cerus' Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm/EST. This presentation reviews data on the efficacy

Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting

Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cerus (CERS) Is Up 2.47% in One Week: What You Should Know

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. After thawing, Pathogen Reduced Cryoprecipitated Fibrinogen Complex remains transfusion-ready at roo

Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Cerus (CERS) Rating Upgrade to Buy

Cerus Corporation (CERS) CEO Obi Greenman on Q3 2020 Results - Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales growth in the U.S. as well as plasma and platelet kit sales from the EMEA region. Total revenue was composed of (in millions, except %):     Three Months Ended   September 30, Change   2020   2019   $   % Prod

Cerus Corporation Announces Record Third Quarter 2020 Results

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cerus (CERS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the

Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020

Gossamer Bio Inc

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1 million. This research is consistent with the FDA’s strategy for developing proactive, foundational interventions to ensure blood sa

Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd through October 5th. This year’s Virtual Annual Meeting remains one of the largest scientific symposiums focused on the field of transfusion medicine. Scientists and clinicians from around the globe will share the latest research and practice-changing resources in the fields of blood and biotherapies.

Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting

ADMA Biologics

AstraZeneca

BioNTech SE

Liminal BioSciences

Pfizer

Sonnet BioTherapeutics

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Biotech Boom: The Race for COVID-19 Vaccines

Kamada

T2 Biosystems

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

3 Plasma Stocks to Win Big on FDA's Convalescent EUA

Grifols, S.A.

ThermoGenesis Holdings, Inc

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.

News for Cerus Stock (CERS)